Skip to main content

Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells


Prolonged life expectancy, life style and environmental changes have caused a changing disease pattern in developed countries towards an increase of degenerative and autoimmune diseases. Stem cells have become a promising tool for their treatment by promoting tissue repair and protection from immune-attack associated damage. Patient-derived autologous stem cells present a safe option for this treatment since these will not induce immune rejection and thus multiple treatments are possible without any risk for allogenic sensitization, which may arise from allogenic stem cell transplantations. Here we report the outcome of treatments with culture expanded human adipose-derived mesenchymal stem cells (hAdMSCs) of 10 patients with autoimmune associated tissue damage and exhausted therapeutic options, including autoimmune hearing loss, multiple sclerosis, polymyotitis, atopic dermatitis and rheumatoid arthritis. For treatment, we developed a standardized culture-expansion protocol for hAdMSCs from minimal amounts of fat tissue, providing sufficient number of cells for repetitive injections. High expansion efficiencies were routinely achieved from autoimmune patients and from elderly donors without measurable loss in safety profile, genetic stability, vitality and differentiation potency, migration and homing characteristics. Although the conclusions that can be drawn from the compassionate use treatments in terms of therapeutic efficacy are only preliminary, the data provide convincing evidence for safety and therapeutic properties of systemically administered AdMSC in human patients with no other treatment options. The authors believe that ex-vivo-expanded autologous AdMSCs provide a promising alternative for treating autoimmune diseases. Further clinical studies are needed that take into account the results obtained from case studies as those presented here.


In the 21st century, live expectancy has rapidly progressed as has the number of previously uncommon diseases with no treatment. Stem cell based therapies are suggested to be able to repair and regenerate tissues in diseases associated with age, changed life style and environmental exposure, such as autoimmune disease and stroke. In particular, mesenchymal stem cells (MSCs) have been applied to treat these diseases [13]. However, the lack of optimized culture protocols for achieving sufficient number of cells, safety issues concerning ex-vivo-expanded cells, the possible reduction in potency of stem cells derived from aged people and patients with autoimmune disease has put into question clinical applications of autologous stem cells in these patients.

In order to apply human autologous adipose tissue derived MSC (hAdMSC) in the clinical setting, we developed a standardized protocol to isolate and culture-expand AdMSC from minimal amounts of fat in vitro, achieving sufficient cell numbers for multiple therapeutic inventions [4]. Expanded AdMSCs maintained the potency for effective differentiation independently of donor age and disease status [5]. The confirmed genetic stability and in vivo safety of ex-vivo-expanded hAdMSCs in animal models and patients [4] indicate that AdMSCs from older persons are applicable for autologous therapy and are comparable to those derived from young donors [5]. Furthermore, we investigated the migration ability of hAdMSCs and their in vivo homing in animal model after systemic infusion.

MSC include a number of stem cells with an inherent ability for self-renewal and differentiation potential for mesodermal and other embryonic lineages, including adipocytes, osteocytes, chondrocytes, hepatocytes, neurons, muscle cells and epithelial cells [68], depending on the surrounding microenvironment. A large body of evidence demonstrated that MSC commonly have immunomodulatory and anti-inflammatory properties [912]. While the differentiation properties of MSC seem to dependent on microenvironmental clues in vivo, the immunomodulatory effects appear to be rather intrinsic and thus present an attractive basis for the therapy of autoimmune and inflammatory diseases by systemic infusion. Moreover, intrinsic properties of MSC demonstrated secretion of various factors, modulation of the local environment and activation of endogenous progenitor cells [13, 14]. Hence, MSC therapy evoked therapeutic promises for graft-versus-host disease (GVHD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), diabetes, myocardial infarction, thyroditis and different types of neurological disorders, among others [1523].

Various routes of administration of MSCs, including intravenous (i.v.) [24], intraarterial [25] or intracerebral [26] were reported for stem cell application. Of these routes, i.v. is a convenient strategy to deliver cells and therapeutic effects to the injury site. Intravenously injected MSC may be transiently trapped in the lungs, sequestered in the spleen, and are predominantly eliminated by kidneys [27]. Initial accumulation of MSC in the lungs may induce secretion of secondary anti inflammatory effectors [28].The recent demonstration of in vivo homing properties of bone marrow derived MSCs and AdMSCs has further stimulated i.v. application of MSC for therapy [29]. In this review, we describe several cases of autologous AdMSCs application in autoimmune conditions, including autoimmune hearing loss, MS, polymyotitis (PM), atopic dermatitis (AD) and RA. We suggest that multiple infusions of AdMSC may establish immune homeostasis over long periods of time.

Phenotype and differentiation potentials of MSCs

Minimal criteria have been proposed to define MSCs by the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy. These are: 1) plastic adherence ability; 2) lack of hematopoietic markers, such as CD45, CD34, CD14, CD11b, CD79α, CD 19, or HLA-DR; 3) tripotential mesodermal differentiation potency into osteoblasts, chondrocytes, and adipocytes; and 4) immunomodulatory capability [30]. In addition to their mesodermal differentiation capability, MSCs were also shown to differentiate in vitro into the ectodermal lineage such as neurons, but also into the endodermal lineage such as myocytes and hepatocytes [7, 31]. The conditions for differentiation of engrafted MSCs in vivo might be more complex and regulated by microenvironmental cluses of local tissues. For example, MSCs engrafted into heart could differentiate into cardiomyocytes, smooth muscle cells, and vascular endothelial cells [3234]. In addition, through a series of signals from local tissue, engrafted MSCs can be induced to secrete diverse cytokines that posses trophic and immunomodulatory functions and subsequently contribute to tissue repair and regeneration [11].

Sources of MSCs

MSC were first isolated as fibroblast colony-forming units (CFU-Fs) or marrow stromal cells from bone marrow (BMMSC) by Friedenstein and colleagues [35]. Their most common name is based on their property of differentiate into a variety of mesodermal tissues including bone, cartilage and fat. MSCs were found in various organs and tissues, including fat, periosteum, synovial membrane, synovial fluid, muscle, dermis, deciduous teeth, pericytes, trabecular bone, infrapatellar fat pad, articular cartilage, umbilical cord and cord blood [36, 37], and placenta [38].

BMMSCs have first been applied for therapy [39, 40]. However, aspirating BM from the patient is an invasive procedure that yields only low numbers of cells (about 1-10 per 1 × 105 or 0.0001-0.01% of all BM nucleated cells), requiring high expansion rates [41]. Furthermore, the therapeutic potential of BMMSCs may be diminished with increasing donor age and is associated with declining differentiation capacity and reduced vitality in vitro [42]. In any case, for autologous transplantation, expanded BMMSCs and AdMSCs have safely been applied in numerous human studies [4, 39, 40].

Adipose mesenchymal stem cells

Adipose tissue is an attractive source of MSCs for autologous stem cell therapy, because adipose tissue is easily obtainable in sufficient quantities using a minimally invasive procedure [23, 43]. In addition, adipose tissues contain more MSCs than BM (about 100, 000 MSCs per gram of fat) [44]. Moreover, differentiation and immunomodulatory potencies of AdMSCs are equivalent to those of BMMSCs [23].

The efficacy of AdMSCs in treating various diseases has been reported in vivo [45]. Local or systemic administration of AdMSCs was reported to have repair capacity in myocardial infarction [19] liver injury [24], hypoxia-ischemia-induced brain damage [46], allergic rhinitis [47] and muscular dystrophy [48]. Furthermore, AdMSCs are immune regulatory and potentially suitable to treat immune-related diseases including GVHD [15], MS [16], rheumatic disease [17, 18] and thyroditis [20].

Establishment of standard culture-expansion procedure of hAdMSCs for clinical applications

Due to the small number of MSC in tissues, ex vivo expansion is required to generate the cell quantities required to achieve therapeutic results with MSCs through systemic delivery. In case of BMMSCs, however, long-term culture alters the quality of MSCs, including morphological changes, attenuated expression of specific surface markers, reduced proliferative capacity, differentiation potential [4952], and trophic activity [53].

To produce sufficient numbers of hAdMSCs for stem cell therapy, optimized culture conditions were developed [4], which allow proliferation of hAdMSC from minimal amounts of fat since large amounts of fat are rarely obtainable from patients suffering from incurable diseases. Usage of a special cannular maximizes survival rate of stem cells in fat tissues and a 3 times higher rate of subsequent early stem cell attachment when compared to other devices. The developed cell collection, cultivation and expansion protocol requires less than 5 g fat to obtain more than 109 cells (after 3 passages). To improve proliferation and differentiation of AdMSC, we tested more than 15 commercially available culture media and eventually developed the hAdMSC culture media, named as RCME (MSC attachment media) and RKCM (MSC proliferation media) [4]. These media provide high viability, shortened doubling times and maintained morphology and improved potency.

The characteristics, stability, toxicity, and tumorigenicity of the culture-expanded hAdMSCs were determined in animals and in human studies [4]. With regard to the safety of culture-expanded stem cells in vitro, genetically stability and consistency on the morphological, immunophenotypic, and differentiation characteristics, as well as toxicity and tumorigenicity need to be verified. We demonstrated that cultured hAdMSCs showed the typical immunophenotype and differentiation capability of MSCs [4]; cells expressed MSC markers CD90, CD105, CD44 and CD29, but did not express hematopoietic or endothelial markers (CD31, CD34 and CD45) and differentiated to adipogenic, osteogenic, neurogenic, myogeneic and chondrogeneic lineages in vitro. Culture-expanded hAdMSCs were genetically stable for at least 12 passages as determined by karyotype and single nucleotide polymorphism (SNP) assays.

Cells suspended in physiological saline maintained their MSC properties, viability and potency at cold storage conditions (2 to 8°C) for at least 72 h, a critical time period for shipping stem cells into the clinic. However, we noticed that physical vibration during shipment might negatively impact cell viability. No evidence of bacterial, fungal, or mycoplasma contamination was observed in cells tested before shipping and cell viability evaluated by trypan blue exclusion was > 95% prior to cell transplantation.

In vivo safety of expanded hAdMSCs

To test the toxicity of hAdMSCs, different cell doses were intravenously injected into immunodeficient severe combined immunodeficiency (SCID) mice, and mice were observed for 13 weeks. Even at the highest cell dose (2.5 × 108 cells/kg body weight), mice showed no sign of discomfort. Although the safety of i.v. injection of culture expanded autologous and allogenic MSCs has been confirmed in patients [54] in numerous human clinical studies including osteogenesis imperfect [55], metachromatic leukodystrophy [56], acute myocardial infarction [57] and GVHD [58], there were some reports presenting that MSCs can induce sarcoma [59] or facilitate the growth of tumors [60]. In order to test tumorigenicity of hAdMSCs, we performed a tumorigenicity test in Balb/c-nude mice for 26 weeks. Even at the highest cell dose (2 × 108 MSCs/kg, subcutaneous injection), no evidence of tumor development was found. The safety of hAdMSCs was further investigated in a phase I human clinical trial, with no serious adverse event after i.v. administration of 4 × 108 hAdMSCs within an observation period of 12 weeks [4]. The minor adverse events found are common to spinal cord injury patients and disappeared spontaneously or were alleviated with medication. One idiopathic case of asymptomatic hyperthyroidism that did not require medical treatment remained sustained during follow-up. Based on these studies, we conclude that the systemic administration of hAdMSCs is safe and does not induce tumor development. In line with these data, Vilalta et al. [61] reported that hAdMSCs implanted in mice tended to maintain a steady state, and no detectable chromosomal abnormalities or tumors formed during the 8 months of residence in the host's tissues. Notably, the development of sarcoma in the study of Tolar et al was due to cytogenetically abnormal culture-expanded MSCs [59]. In addition, Izadpanah et al. [62] demonstrated that long-term cultivation of MSC beyond passage 20 may result in their transformation to malignant cells. These results indicate that it is essential to control genetic stability of culture-expanded cells.

Comparison of neural cell differentiation of hAdMSC derived from young and old donors

Because many diseases that are candidates for stem cells therapy are age-associated degenerative diseases, stem cells obtained from the elderly for autologous use should possess potency in order to have therapeutic effects. In terms of BMMSCs, there have been controversial results regarding the effects of aging. Using human BMMSCs from juveniles and adults seeded onto three-dimensional scaffolds, Mendes et al. [63] have demonstrated that actual bone formation decreased significantly as patient age increased. Huibregtse et al. [64] demonstrated that overall reduction in colony-forming efficiency was observed in rabbit BMMSCs derived from older animals. Bergman et al. [65] demonstrated that differences in basal proliferation rates were observed between young and old BMMSCs isolated from mice, while production of early markers of osteoblastic differentiation in vitro were equivalent. Stenderup et al. [42] have shown that human BMMSC isolated from older donors have a decreased lifespan and rate of population doubling, while both BMMSCs formed similar amounts of bone both in vitro and in vivo [51].

Adipose derived MSC seem not to undergo the same senescence pattern as BMMSC [66, 67]. When hAdMSC were derived from elderly (mean 71.4 years) and young donors (mean 36.4 years), cells from both age groups showed similar proliferation, osteogenic differentiation and senescence marker patterns, while BMMSC from the same cohorts showed reduced proliferation, decreased differentiation and increased senescence [66]. In concordance with these findings are data from murine AdMSC derived from senile osteoporotic SAMP6 mice, which showed maintenance of telomere length, telomerase activity and osteogenic differentiation [67]. In order to determine the potency of hAdMSCs isolated from donors aged thirty, forty and fifty, their proliferation and differentiation potential to neural cells was investigated [5]. It was demonstrated that cell number, viability, morphology and neural differentiation potential were not different between hAdMSC of different age and passage. The results suggest that autologous adipose derived stem cells from aged people may be applied for stem cell therapy of age-dependent neural disease with the same stem cell quality and ability as stem cells derived from younger patients.

Distribution, migration and homing potential of transplanted MSCs after intravenous injection

Distribution of MSCs after i.v. injection

After i.v. delivery, MSCs are generally found at low or very low frequencies in most target organs, as shown by histology, polymerase chain reaction or by immunohistochemistry [6870]. Deak et al. [71] performed systematic kinetic assessments in non-injury models using enhanced green fluorescent protein transfected murine MSCs. They demonstrated that 24 hr after MSC application, the most frequently positive organs were lungs, liver, kidney, skin, and gut among investigated tissues. In baboons, Devine et al. [69] demonstrated that high concentration of transplant specific DNA was observed in gastrointestinal tissues. They also showed that kidney, lung, liver, thymus, and skin have relatively high amounts of DNA equivalents. Based on their studies, levels of engraftment in these tissues were estimated, ranging from 0.1 to 2.7%, with similar results with autologous and allogeneic cells [69]. After systemic administration, Lee et al. [28] found 80% of the infused MSCs in the lungs of mice 15 min after infusion, whereas after 4 days the specific signal for the presence of human MSCs decreased to 0.01%. Of importance, clinical studies with systemically delivered human MSCs did not induce significant intolerance symptoms from the pulmonary or circulatory systems, while murine MSCs displayed a somewhat different behavior. Deak et al. [72] have demonstrated in a C57BL/6 syngenic murine MSCs transfusion model, that in contrast to human MSCs, murine MSCs home to lungs and might clog in the lungs.

Migration and homing potential of MSCs after i.v. injection

A number of in vivo studies have shown that systemically infused MSCs could migrate to injured, inflamed tissues and exert therapeutic effects [73, 74]. BMMSCs intravenously delivered to rats following myocardial infarction localize in the infarct region and improve ventricular function, while MSCs delivered to non-infarcted rats localize to the BM [75]. Localized abdomen irradiation significantly enhances MSC homing specifically to radiation-injured tissues in mice [76]. A recent study demonstrated the homing properties of i.v. administered hAdMSCs to cell-damaged areas in an allergic rhinitis animal model [47]. The relative organ distribution of fluorescence-labeled hAdMSCs was assessed by us in brain, spinal cord, spleen, thymus, kidney, liver, lung, and heart after i.v. injection in spinal cord injury rats by fluorescence microscopy and human specific Alu PCR. In the injured region of spinal cord, a relatively high percentage of AdMSCs (13%) was found, while most cells remained in spleen (40%) and thymus (21%) [data not shown].

Numerous studies showed the involvement of chemokines or growth factors in MSCs trafficking to the injury region. The interactions of stromal cell-derived factor-1α (SDF-1α)- and C-X-C chemokine receptor type 4 (CXCR4) mediated the trafficking of transplanted BMMSCs in a rat model of left hypoglossal nerve injury. In addition, BMMSCs were attracted by chemokines that are presented in the supernatants of primary cultures of human pancreatic islets culture in vitro and in vivo[77]. When we compared soluble factors by in vitro migration assay, platelet derived growth factor (PDGF)-AB and transforming growth factor-ß1 (TGF-β1) were most potent for migration activity of hAdMSCs [78]. hAdMSCs pre-stimulated with tumor necrosis factor (TNF-α) showed the highest migration activity. When analyzed by flow cytometry and reverse transcriptase-polymerase chain reaction, hAdMSC expressed C-C chemokine receptor type 1 (CCR1), CCR7, C-X-C chemokine receptor type 4 (CXCR4), CXCR5, CXCR6, EGFR (EGF receptor), FGFR1 (FGF receptor 1), TGFBR2 (TGF receptor 2), TNFRSF1A (TNF receptor 1), PDGFRA (PDGF receptor A) and PDGFRB (PDGF receptor B) at protein and mRNA levels. This study indicates that the migration of hAdMSCs is controlled by various growth factors or chemokines. Hence, modulating the homing capacity of hAdMSCs in vivo could stimulate its migration into injured sites after i.v. administration, and thereby improve their therapeutic potential.

Immunomodulation and anti-inflammatory effects by MSCs

Several characteristics may play a role for the immune regulatory capability and anti-inflammatory effects of MSCs: 1) MSCs have low immunogenicity due to low expression levels of major histocompatibility complex-I (MHC-I) and no expression of MHC-II molecules and costimulatory molecules including B7-1 (CD80), B7-2 (CD86), or CD40 [79], (2) MSCs secrete soluble factors such as interleukin (IL)-6 and macrophage-colony stimulating factor [80] and suppress the activation and proliferation of T and B lymphocytes, and interfere with differentiation, maturation and function of dendritic cells, (3) MSC release anti-inflammatory and anti-apoptotic molecules and hence may protect damaged tissues [79, 81].

Due to these properties, MSC transplantation has been used for the treatment of GVHD, and several autoimmune diseases, including autoimmune thyroditis [20], RA [17, 18] and MS [16] and implicated for allogeneic stem cell transplantation. Systemic infusion of AdMSCs controlled lethal GVHD in mice transplanted with haploidentical hematopoietic stem cell grafts when the MSCs were injected early after transplantation [15] although ongoing clinical studies with allogeneic BMMSC were not successful. Therapeutic efficacy of BMMSCs was reported in the animal model of MS [16]. In this experimental autoimmune encephalomyelitis (EAE) model, i.v. infusion of MSCs decreased clinical symptoms when MSCs were injected before or at the onset of the disease. In an experimental collagen-induced arthritis (CIA) study, a single intraperitoneal injection of BMMSCs prevented the occurrence of severe arthritis, and was associated with a decrease in serum levels of pro-inflammatory cytokines [18]. Human AdMSCs have been demonstrated to ameliorate experimental autoimmune thyroiditis via down-regulation of Th1 cytokines [20]. Systemic infusion of hAdMSCs prevented lymphocyte infiltration to thyroid glands, decreased the production of pro-inflammatory cytokines and improved Th1/Th2 balance [20]. MSCs suppressed T-cell proliferation and cytokine production in response to alloantigen and nonspecific antigen, and prolong skin graft survival in vivo [82]. In addition, MSCs inhibit function of B cells [83], natural killer cells [84] and dendritic cells [85]. The immunomodulatory function of MSC was mediated both by soluble factors [86], and by direct cell to cell interactions [87].

Whether MSC derived from patients with autoimmune diseases will have therapeutic functions after autologous transplantation in a clinical situation is controversial and has not been addressed clinically [88]. Papadaki et al. [89] showed that while BMMSCs isolated from RA patients were found to be impaired in their ability to support hematopoiesis, BMMSCs isolated from MS patients displayed normal ability [89, 90]. Other data demonstrated that BMMSCs derived from patients with RA, MS, autoimmune SLE, systemic sclerosis (SSc) and Sjogren's syndrome retained their immunomodulatory capabilities in vitro [91, 92].

Clinical application of MSCs in autoimmune diseases

Given their confirmed in vivo safety and the rationale that MSCs possess immunomodulatory and anti-inflammatory properties, compassionate-use treatments for autoimmune diseases were initiated in patients after other treatment options were exhausted. All patients provided informed consent to the treatment. Here, we describe treatment of AdMSCs in autoimmune hearing loss (AIED), MS, PM, AD and RA. Details on the patients disease and treatment histories, disease status and treatments are provided in Table 1 and Additional File 1; Case Reports, Table S1 and Figure S1. Additional clinical scores for AD before and after treatment are shown in Table 2. Patient analysis was based mostly on clinical parameters. In some cases, immunological and blood status parameters were also measured (cases 3, 4, 5, 8, 9, 10); all cases showed decrease in inflammatory responses and eosinophil counts.

Table 1 Summary of hAdMSC treatments of 10 patients with different autoimmune-associated diseases.
Table 2 SCORing results of AD patients.

For all treatments, 5 g of fat tissues were collected by liposuction, transferred immediately to the GMP facility and Stem Cell Research Center of RNL BIO and culture-expanded for 3 passages using the standard protocol to obtain AdMSCs [4]. The patients received between 1 and 6 i.v. infusions of 200 million AdMSCs suspended in physiological saline (each 100 million cells/100 ml) in different intervals (see Table 1 and Additional File 1; Case Reports). Two patients received additional intrathecal (MS-patient) and intrarticular (RA-patient) injections of cells (Table 1 and Additional File 1; Case Reports and Table S1).


Human AdMSC can be isolated from small amounts of adipose tissue, efficiently expanded to achieve more than 109 cells after 3 to 4 passages independent on donor age and disease status. The sustained potency and genetic stability of the cells make adipose tissue a very attractive source for multipotent cells. Their immunmodulatory function, homing and migratory patterns as well as previous clinical trials suggest that these cells are efficient for treatment for several classes of autoimmune diseases and their application is safe. Here, we demonstrated considerable therapeutic effects of culture-expanded autologous AdMSCs in a variety of autoimmune diseases in the frame of an ethically justified compassionate use application for patients with exhausted therapeutic options. Multiple intravenous infusions of cells resulted in clinical benefit in all treated patients in the follow up period. No adverse events were observed. The data provide first evidence for clinical benefit in autoimmune diseases, yet further scrutiny in controlled clinical trials with a sufficient numbers of patients are needed to draw a definitive conclusion on therapeutic efficacy and long term benefit. Importantly, the data show that multiple AdMSC infusion of up to 1 × 109 cells in a period of less than one month is safe, corroborating data from preclinical and clinical trials using BMMSC and AdMSC. Furthermore, within this small sample size, no evidence of donor age-dependent efficacy, or age dependent in vitro cell expansion rate was found. The autologous stem cell application described here is based on the current state of the art and provides an outlook into treatments for patients suffering from a variety of incurable autoimmune related diseases with no remaining treatment options. While it is shown here that the technology for treatment of autoimmune using autologous AdMSC is in place and the expectations derived from preclinical studies can be confirmed, there is still a limited understanding of the modes of action. In conclusion, the systemic infusion of autologous stem cells described here offers promise for better management of a wide spectrum of autoimmune diseases, independent on patient's age.


  1. 1.

    Si YL, Zhao YL, Hao HJ, Fu XB, Han WD: MSC: Biological characteristics, clinical applications and their outstanding concerns. Ageing Res Rev. 2011, 10: 93-103. 10.1016/j.arr.2010.08.005.

    CAS  PubMed  Google Scholar 

  2. 2.

    Parekkadan B, Milwid JM: Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng. 2010, 12: 87-117. 10.1146/annurev-bioeng-070909-105309.

    PubMed Central  CAS  PubMed  Google Scholar 

  3. 3.

    García-Gómez I, Elvira G, Zapata AG, Lamana ML, Ramírez M, Castro JG, Arranz MG, Vicente A, Bueren J, García-Olmo D: Mesenchymal stem cells: biological properties and clinical applications. Expert Opin Biol Ther. 2010, 10: 1453-1468. 10.1517/14712598.2010.519333.

    PubMed  Google Scholar 

  4. 4.

    Ra JC, Shin IS, Kim SH, Kang SK, Kang BC, Lee HY, Kim YJ, Jo JY, Yoon EJ, Choi HJ, Kwon E: Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev. 2011, 20 (8): 1295-6. 10.1089/scd.2011.0198.

    Google Scholar 

  5. 5.

    Jo JY, Kang SK, Choi IS, Ra JC: Comparison of neural cell differentiation of human adipose mesenchymal stem cells derived from young and old ages. Devel Reprod. 2009, 13: 227-237.

    Google Scholar 

  6. 6.

    Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science. 1999, 284: 143-147. 10.1126/science.284.5411.143.

    CAS  PubMed  Google Scholar 

  7. 7.

    Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM: Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002, 418: 41-49. 10.1038/nature00870.

    CAS  PubMed  Google Scholar 

  8. 8.

    Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH: Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood. 2004, 103: 1669-1675. 10.1182/blood-2003-05-1670.

    CAS  PubMed  Google Scholar 

  9. 9.

    Nauta AJ, Fibbe WE: Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007, 110: 3499-3506. 10.1182/blood-2007-02-069716.

    CAS  PubMed  Google Scholar 

  10. 10.

    Oh JY, Kim MK, Shin MS, Lee HJ, Ko JH, Wee WR, Lee JH: The anti-inflammatory and antiangiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury. Stem Cells. 2008, 26: 1047-1055. 10.1634/stemcells.2007-0737.

    CAS  PubMed  Google Scholar 

  11. 11.

    Ankrum J, Karp JM: Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol Med. 2010, 16: 203-209. 10.1016/j.molmed.2010.02.005.

    PubMed Central  PubMed  Google Scholar 

  12. 12.

    Choi YH, Kurtz A, Stamm C: Mesenchymal stem cells for cardiac cell therapy. Hum Gene Ther. 2011, 22: 3-17. 10.1089/hum.2010.211.

    CAS  PubMed  Google Scholar 

  13. 13.

    Zhang M, Mal N, Kiedrowski M, Chacko M, Askari AT, Popovic ZB, Koc ON, Penn MS: SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J. 2007, 21: 3197-3207. 10.1096/fj.06-6558com.

    CAS  PubMed  Google Scholar 

  14. 14.

    Togel F, Weiss K, Yang Y, Hu Z, Zhang P, Westenfelder C: Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol. 2007, 292: F1626-F1635. 10.1152/ajprenal.00339.2006.

    CAS  PubMed  Google Scholar 

  15. 15.

    Yañez R, Lamana ML, García-Castro J, Colmenero I, Ramírez M, Bueren JA: Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells. 2006, 24: 2582-2591. 10.1634/stemcells.2006-0228.

    PubMed  Google Scholar 

  16. 16.

    Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A: Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005, 106: 1755-1761. 10.1182/blood-2005-04-1496.

    CAS  PubMed  Google Scholar 

  17. 17.

    Djouad F, Bouffi C, Ghannam S, Noël D, Jorgensen C: Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol. 2009, 5: 392-399. 10.1038/nrrheum.2009.104.

    CAS  PubMed  Google Scholar 

  18. 18.

    Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G: Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 2007, 56: 1175-1186. 10.1002/art.22511.

    CAS  PubMed  Google Scholar 

  19. 19.

    Cai L, Johnstone BH, Cook TG, Tan J, Fishbein MC, Chen PS, March KL: IFATS collection: Human adipose tissue-derived stem cells induce angiogenesis and nerve sprouting following myocardial infarction, in conjunction with potent preservation of cardiac function. Stem Cells. 2009, 27: 230-237. 10.1634/stemcells.2008-0273.

    PubMed Central  CAS  PubMed  Google Scholar 

  20. 20.

    Choi EW, Shin IS, Lee HW, Park SY, Park JH, Nam MH, Kim JS, Woo SK, Yoon EJ, Kang SK, Ra JC, Youn HY, Hong SH: Transplantation of CTLA4Ig gene-transduced adipose tissue-derived mesenchymal stem cells reduces inflammatory immune response and improves Th1/Th2 balance in experimental autoimmune thyroiditis. J Gene Med. 2011, 13: 3-16. 10.1002/jgm.1531.

    CAS  PubMed  Google Scholar 

  21. 21.

    Phinney DG, Prockop DJ: Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells. 2007, 25: 2896-2902. 10.1634/stemcells.2007-0637.

    PubMed  Google Scholar 

  22. 22.

    Song H, Song BW, Cha MJ, Choi IG, Hwang KC: Modification of mesenchymal stem cells for cardiac regeneration. Expert Opin Biol Ther. 2010, 10: 309-319. 10.1517/14712590903455997.

    PubMed  Google Scholar 

  23. 23.

    Mizuno H: Adipose-derived stem cells for tissue repair and regeneration: ten years of research and a literature review. J Nippon Med Sch. 2009, 76: 56-66. 10.1272/jnms.76.56.

    PubMed  Google Scholar 

  24. 24.

    Banas A, Teratani T, Yamamoto Y, Tokuhara M, Takeshita F, Osaki M, Kawamata M, Kato T, Okochi H, Ochiya T: IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury. Stem Cells. 2008, 26: 2705-2712. 10.1634/stemcells.2008-0034.

    CAS  PubMed  Google Scholar 

  25. 25.

    Lu D, Li Y, Wang L, Chen J, Mahmood A, Chopp M: Intraarterial administration of marrow stromal cells in a rat model of traumatic brain injury. J Neurotrauma. 2001, 18: 813-819. 10.1089/089771501316919175.

    CAS  PubMed  Google Scholar 

  26. 26.

    Chen J, Li Y, Chopp M: Intracerebral transplantation of bone marrow with BDNF after MCAo in rat. Neuropharmacology. 2000, 39: 711-716. 10.1016/S0028-3908(00)00006-X.

    CAS  PubMed  Google Scholar 

  27. 27.

    Detante O, Moisan A, Dimastromatteo J, Richard MJ, Riou L, Grillon E, Barbier E, Desruet MD, De Fraipont F, Segebarth C, Jaillard A, Hommel M, Ghezzi C, Remy C: Intravenous administration of 99mTc-HMPAO-labeled human mesenchymal stem cells after stroke: in vivo imaging and biodistribution. Cell Transplant. 2009, 18: 1369-1379. 10.3727/096368909X474230.

    PubMed  Google Scholar 

  28. 28.

    Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P, Prockop DJ: Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009, 5: 54-63. 10.1016/j.stem.2009.05.003.

    PubMed Central  CAS  PubMed  Google Scholar 

  29. 29.

    Mosna F, Sensebe L, Krampera M: Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide. Stem Cells. 2010, 19: 1449-1470. 10.1089/scd.2010.0140.

    CAS  Google Scholar 

  30. 30.

    Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006, 8: 315-317. 10.1080/14653240600855905.

    CAS  PubMed  Google Scholar 

  31. 31.

    Tomita Y, Makino S, Hakuno D, Hattan N, Kimura K, Miyoshi S, Murata M, Ieda M, Fukuda K: Application of mesenchymal stem cell derived cardiomyocytes as bio-pacemakers: current status and problems to be solved. Med Biol Eng Comput. 2007, 45: 209-220. 10.1007/s11517-007-0163-4.

    PubMed  Google Scholar 

  32. 32.

    Gojo S, Gojo N, Takeda Y, Mori T, Abe H, Kyo S, Hata J, Umezawa A: In vivo cardiovasculogenesis by direct injection of isolated adult mesenchymal stem cells. Exp Cell Res. 2003, 288: 51-59. 10.1016/S0014-4827(03)00132-0.

    CAS  PubMed  Google Scholar 

  33. 33.

    Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, Miller J, Guetta E, Zipori D, Kedes LH, Kloner RA, Leor J: Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation. 2003, 108: 863-868. 10.1161/01.CIR.0000084828.50310.6A.

    PubMed  Google Scholar 

  34. 34.

    Psaltis PJ, Zannettino AC, Worthley SG, Gronthos S: Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells. 2008, 26: 2201-2210. 10.1634/stemcells.2008-0428.

    PubMed  Google Scholar 

  35. 35.

    Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP: Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968, 6: 230-247. 10.1097/00007890-196803000-00009.

    CAS  PubMed  Google Scholar 

  36. 36.

    Bianco P, Robey PG, Simmons PJ: Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell. 2008, 2: 313-319. 10.1016/j.stem.2008.03.002.

    PubMed Central  CAS  PubMed  Google Scholar 

  37. 37.

    Rebelatto CK, Aguiar AM, Moretao MP, Senegaglia AC, Hansen P, Barchiki F, Oliveira J, Martins J, Kuligovski C, Mansur F, Christofis A, Amaral VF, Brofman PS, Goldenberg S, Nakao LS, Correa A: Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue. Exp Biol Med. 2008, 233: 901-913. 10.3181/0712-RM-356.

    CAS  Google Scholar 

  38. 38.

    Alviano F, Fossati V, Marchionni C, Arpinati M, Bonsi L, Franchina M, Lanzoni G, Cantoni S, Cavallini C, Bianchi F, Tazzari PL, Pasquinelli G, Foroni L, Ventura C, Grossi A, Bagnara GP: Term Amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells in vitro. BMC Dev Biol. 2007, 7: 11-10.1186/1471-213X-7-11.

    PubMed Central  PubMed  Google Scholar 

  39. 39.

    D'Ippolito G, Diabira S, Howard GA, Menei P, Roos BA, Schiller PC: Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci. 2004, 117: 2971-2981. 10.1242/jcs.01103.

    PubMed  Google Scholar 

  40. 40.

    Kassem M, Kristiansen M, Abdallah BM: Mesenchymal stem cells: cell biology and potential use in therapy. Basic Clin Pharmacol Toxicol. 2004, 95: 209-214. 10.1111/j.1742-7843.2004.pto950502.x.

    CAS  PubMed  Google Scholar 

  41. 41.

    Gronthos S, Zannettino AC, Hay SJ, Shi S, Graves SE, Kortesidis A, Simmons PJ: Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci. 2003, 116: 1827-1835. 10.1242/jcs.00369.

    CAS  PubMed  Google Scholar 

  42. 42.

    Stenderup K, Justuesen J, Clausen C, Kassem M: Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone. 2003, 6: 919-926.

    Google Scholar 

  43. 43.

    Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH: Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002, 13: 4279-4295. 10.1091/mbc.E02-02-0105.

    PubMed Central  CAS  PubMed  Google Scholar 

  44. 44.

    Sen A, Lea-Currie YR, Sujkowska D, Franklin DM, Wilkison WO, Halvorsen YD, Gimble JM: Adipogenic potential of human adipose derived stromal cells from multiple donors is heterogeneous. J Cell Biochem. 2001, 81: 312-319. 10.1002/1097-4644(20010501)81:2<312::AID-JCB1046>3.0.CO;2-Q.

    CAS  PubMed  Google Scholar 

  45. 45.

    Mizuno H: Adipose-derived stem and stromal cells for cell-based therapy: current status of preclinical studies and clinical trials. Curr Opin Mol Ther. 2010, 12: 442-449.

    CAS  PubMed  Google Scholar 

  46. 46.

    Wei X, Du Z, Zhao L, Feng D, Wei G, He Y, Tan J, Lee WH, Hampel H, Dodel R, Johnstone BH, March ML, Farlow MR, Du Y: IFATS collection: The conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats. Stem Cells. 2009, 27: 478-488. 10.1634/stemcells.2008-0333.

    CAS  PubMed  Google Scholar 

  47. 47.

    Cho KS, Park HK, Park HY, Jung JS, Jeon SG, Kim YK, Roh HJ: IFATS collection: Immunomodulatory effects of adipose tissue-derived stem cells in an allergic rhinitis mouse model. Stem Cells. 2009, 27: 259-265. 10.1634/stemcells.2008-0283.

    CAS  PubMed  Google Scholar 

  48. 48.

    Bacou F, el Andalousi RB, Daussin PA, Micallef JP, Levin JM, Chammas M, Casteilla L, Reyne Y, Nougues J: Transplantation of adipose tissue-derived stromal cells increases mass and functional capacity of damaged skeletal muscle. Cell Transplant. 2004, 13: 103-111.

    PubMed  Google Scholar 

  49. 49.

    Wislet-Gendebien S, Leprince P, Moonen G, Rogister B: Regulation of neural markers nestin and GFAP expression by cultivated bone marrow stromal cells. J Cell Sci. 2003, 116: 3295-3302. 10.1242/jcs.00639.

    CAS  PubMed  Google Scholar 

  50. 50.

    Bonab MM, Alimoghaddam K, Talebian F, Ghaffari SH, Ghavamzadeh A, Nikbin B: Aging of mesenchymal stem cell in vitro. BMC Cell Biol. 2006, 10: 7-14.

    Google Scholar 

  51. 51.

    Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, Benes V, Blake J, Pfister S, Eckstein V, Ho AD: Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One. 2008, 3: e2213-10.1371/journal.pone.0002213.

    PubMed Central  PubMed  Google Scholar 

  52. 52.

    Wagner W, Ho AD, Zenke M: Different facets of aging in human mesenchymal stem cells. Tissue Eng Part B Rev. 2010, 16: 445-453. 10.1089/ten.teb.2009.0825.

    PubMed  Google Scholar 

  53. 53.

    Briquet A, Dubois S, Bekaert S, Dolhet M, Beguin Y, Gothot A: Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward NOD/SCID-repopulating cells and committed progenitor cells of B lymphoid and myeloid lineages. Haematologica. 2010, 95: 47-56. 10.3324/haematol.2009.008524.

    PubMed Central  PubMed  Google Scholar 

  54. 54.

    Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI: Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant. 1995, 16: 557-564.

    CAS  PubMed  Google Scholar 

  55. 55.

    Horwitz EM, Gordon PL, Koo WKK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T: Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci. 2002, 99: 8932-8937. 10.1073/pnas.132252399.

    PubMed Central  CAS  PubMed  Google Scholar 

  56. 56.

    Koç ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W: Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant. 2002, 30: 215-222. 10.1038/sj.bmt.1703650.

    PubMed  Google Scholar 

  57. 57.

    Chen S, Fang W, Ye F, Liu Y, Qian J, Shan S, Zhang J, Chunhua RZ, Liao L, Lin S, Sun J: Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. The Am J Cardiol. 2004, 94: 92-95. 10.1016/j.amjcard.2004.03.034.

    PubMed  Google Scholar 

  58. 58.

    Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringdén O: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008, 371: 1579-1586. 10.1016/S0140-6736(08)60690-X.

    CAS  PubMed  Google Scholar 

  59. 59.

    Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, Xia L, Zhou N, Riddle M, Schroeder TM, Westendorf JJ, McIvor RS, Hogendoorn PCW, Szuhai K, Oseth L, Hirsch B, Yant SR, Kay MA, Peister A, Prockop DJ, Fibbe WE, Blazar BR: Sarcoma derived from cultured mesenchymal stem cells. Stem Cells. 2007, 25: 371-379. 10.1634/stemcells.2005-0620.

    CAS  PubMed  Google Scholar 

  60. 60.

    Zimmerlin L, Donnenberg AD, Rubin JP, Landreneau RJ, Basse P, Donnenberg VS: Regenerative therapy and cancer: In vitro and in vivo studies of the interaction between adipose-derived stem cells and breast cancer cells from clinical isolates. Tissue Eng. 2011, 17: 93-106.

    CAS  Google Scholar 

  61. 61.

    Vilalta M, Dégano IR, Bagó J, Gould D, Santos M, García-Arranz M, Ayats R, Fuster C, Chernajovsky Y, García-Olmo D, Rubio N, Blanco J: Biodistribution, long-term survival, and safety of human adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high sensitivity non-invasive bioluminescence imaging. Stem Cells Dev. 2008, 17: 993-1003. 10.1089/scd.2007.0201.

    PubMed  Google Scholar 

  62. 62.

    Izadpanah R, Kaushal D, Kriedt C, Tsien F, Patel B, Dufour J, Bunnell BA: Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res. 2008, 68: 4229-4238. 10.1158/0008-5472.CAN-07-5272.

    PubMed Central  CAS  PubMed  Google Scholar 

  63. 63.

    Mendes SC, Tibbe JM, Veenhof M, Bakker K, Both S, Platenburg PP, Oner FC, de Bruijn JD, van Blitterswijk CA: Bone tissue-engineered implants using human bone marrow stromal cells: Effect of culture conditions and donor age. Tissue Eng. 2002, 8: 911-920. 10.1089/107632702320934010.

    CAS  PubMed  Google Scholar 

  64. 64.

    Huibregtse BA, Johnstone B, Goldberg VM, Caplan AI: Effect of age and sampling site on the chondro-osteogenic potential of rabbit marrow-derived mesenchymal progenitor cells. J Orthop Res. 2000, 18: 18-24. 10.1002/jor.1100180104.

    CAS  PubMed  Google Scholar 

  65. 65.

    Bergman RJ, Gazit D, Kahn AJ, Gruber H, McDougall S, Hahn TJ: Age-related changes in osteogenic stem cells in mice. J Bone Miner Res. 1996, 11: 568-577.

    CAS  PubMed  Google Scholar 

  66. 66.

    Chen HT, Lee MJ, Chen CH, Chuang SC, Chang LF, Ho ML, Hung SH, Fu YC, Wang YH, Wang HI, Wang GJ, Kang L, Chang JK: Proliferation and differentiation potential of human adipose-derived mesenchymal stem cells isolated from elderly patients with osteoporotic fractures. J Cell Mol Med. 2011,

    Google Scholar 

  67. 67.

    Mirsaidi A, Kleinhans KN, Rimann M, Tiaden AN, Stauber M, Rudolph KL, Richards PJ: Telomere length, telomerase activity and osteogenic differentiation are maintained in adipose-derived stromal cells from senile osteoporotic SAMP6 mice. J Tissue Eng Regen Med. 2011,

    Google Scholar 

  68. 68.

    Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI: The dynamic in vivo distribution of bone marrow derived mesenchymal stem cells after infusion. Cells Tiss Organs. 2001, 169: 12-20. 10.1159/000047856.

    CAS  Google Scholar 

  69. 69.

    Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R: Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood. 2003, 101: 2999-3001. 10.1182/blood-2002-06-1830.

    CAS  PubMed  Google Scholar 

  70. 70.

    Bensidhoum M, Chapel A, Francois S, Demarquay C, Mazurier C, Fouillard L, Bouchet S, Bertho JM, Gourmelon P, Aigueperse J, Charbord P, Gorin NC, Thierry D, Lopez M: Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood. 2004, 103: 3313-3319. 10.1182/blood-2003-04-1121.

    CAS  PubMed  Google Scholar 

  71. 71.

    Deak E, Seifried E, Henschler R: Homing pathways of mesenchymal stromal cells (MSCs) and their role in clinical applications. Int Rev Immunol. 2010, 295: 514-529.

    Google Scholar 

  72. 72.

    Deak E, Rűster B, Keller L, Eckert K, Fichtner I, Seifried E, Henschler R: Suspension medium influences interaction of mesenchymal stromal cells with endothelium and pulmonary toxicity after transplantation in mice. Cytotherapy. 2010, 12: 260-264. 10.3109/14653240903401840.

    CAS  PubMed  Google Scholar 

  73. 73.

    Chapel A, Bertho JM, Bensiodhoum M, Fouillard L, Young RG, Frick J, Demarquay C, Cuvelier F, Mathieu E, Trompier F, Dudoignon N, Germain C, Mazurier C, Aigueperse J, Borneman J, Gorin NC, Goumelon P, Thierry D: Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi organ failure syndrome. J Gene Med. 2003, 5: 1028-1038. 10.1002/jgm.452.

    PubMed  Google Scholar 

  74. 74.

    Chavakis E, Urbich C, Dimmeler S: Homing and engraftment of progenitor cells: a prerequisite for cell therapy. J Mol Cell Cardiol. 2008, 45: 514-522. 10.1016/j.yjmcc.2008.01.004.

    CAS  PubMed  Google Scholar 

  75. 75.

    Saito T, Kuang J, Bittira B, Al-Khaldi A, Chiu RCJ: Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Ann Thorac Surg. 2002, 74: 19-24. 10.1016/S0003-4975(02)03591-9.

    PubMed  Google Scholar 

  76. 76.

    Mouiseddine M, François S, Semont A, Sache A, Allenet B, Mathieu N, Frick J, Thierry D, Chapel A: Human mesenchymal stem cells home specifically to radiation-injured tissues in a non-obese diabetes/severe combined immunodeficiency mouse model. Br J Radiol. 2007, 80: S49-55. 10.1259/bjr/25927054.

    CAS  PubMed  Google Scholar 

  77. 77.

    Sordi V, Malosio ML, Marchesi F, Mercalli A, Melzi R, Giordano T, Belmonte N, Ferrari G, Leone BE, Bertuzzi F, Zerbini G, Allavena P, Bonifacio E, Piemonti L: Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood. 2005, 106: 419-427. 10.1182/blood-2004-09-3507.

    CAS  PubMed  Google Scholar 

  78. 78.

    Baek SJ, Kang SK, Ra JC: In vitro migration capacity of human adipose-derived mesenchymal stem cells and their expression of a distinct set of chemokine and growth factor receptors. Exp Mol Med. 2011,

    Google Scholar 

  79. 79.

    Le Blanc K, Ringden O: Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007, 262: 509-525. 10.1111/j.1365-2796.2007.01844.x.

    CAS  PubMed  Google Scholar 

  80. 80.

    Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, Bony C, Apparailly F, Cantos C, Jorgensen C, Noel D: Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells. 2007, 25: 2025-2032. 10.1634/stemcells.2006-0548.

    CAS  PubMed  Google Scholar 

  81. 81.

    Meirelles Lda S, Fontes AM, Covas DT, Caplan AI: Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009, 20: 419-427. 10.1016/j.cytogfr.2009.10.002.

    PubMed  Google Scholar 

  82. 82.

    Rasmusson I, Ringdén O, Sundberg B, Le Blanc K: Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res. 2005, 305: 33-41. 10.1016/j.yexcr.2004.12.013.

    CAS  PubMed  Google Scholar 

  83. 83.

    Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V, Uccelli A: Human mesenchymal stem cells modulate B-cell functions. Blood. 2006, 107: 367-372. 10.1182/blood-2005-07-2657.

    CAS  PubMed  Google Scholar 

  84. 84.

    Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L: Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood. 2008, 111: 1327-1333.

    CAS  PubMed  Google Scholar 

  85. 85.

    Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, Mao N: Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 2005, 105: 4120-4126. 10.1182/blood-2004-02-0586.

    CAS  PubMed  Google Scholar 

  86. 86.

    Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y: Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008, 2: 141-150. 10.1016/j.stem.2007.11.014.

    CAS  PubMed  Google Scholar 

  87. 87.

    Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F: Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003, 101: 3722-3729. 10.1182/blood-2002-07-2104.

    CAS  PubMed  Google Scholar 

  88. 88.

    Al-Refu K, Goodfield M: Hair follicle stem cells in the pathogenesis of the scarring process in cutaneous lupus erythematosus. Autoimmun Rev. 2009, 8: 474-477. 10.1016/j.autrev.2008.12.015.

    PubMed  Google Scholar 

  89. 89.

    Papadaki HA, Kritikos HD, Gemetzi C, Koutala H, Marsh JC, Boumpas DT Eliopoulos GD: Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alphamediated effect. Blood. 2002, 99: 1610-1619. 10.1182/blood.V99.5.1610.

    CAS  PubMed  Google Scholar 

  90. 90.

    Papadaki HA, Tsagournisakis M, Mastorodemos V, Pontikoglou C, Damianaki A, Pyrovolaki K, Stamatopoulos K, Fassas A, Plaitakis A, Eliopoulos GD: Normal bone marrow hematopoietic stem cell reserves and normal stromal cell function support the use of autologous stem cell transplantation in patients with multiple sclerosis. Bone Marrow Transplant. 2005, 36: 1053-1063. 10.1038/sj.bmt.1705179.

    CAS  PubMed  Google Scholar 

  91. 91.

    Bocelli-Tyndall C, Bracci L, Spagnoli G, Braccini A, Bouchenaki M, Ceredig R, Pistoia V, Martin I, Tyndall A: Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology. 2007, 46: 403-408. 10.1093/rheumatology/kel267.

    CAS  PubMed  Google Scholar 

  92. 92.

    Mazzanti B, Aldinucci A, Biagioli T, Barilaro A, Urbani S, Dal PS, Amato MP, Siracusa G, Crescioli C, Manuelli C, Bosi A, Saccardi R, Massacesi L, Ballerini C: Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment. J Neuroimmunol. 2008, 199: 142-150. 10.1016/j.jneuroim.2008.05.006.

    CAS  PubMed  Google Scholar 

  93. 93.

    McCabe BF: Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol. 1979, 88: 585-589.

    CAS  PubMed  Google Scholar 

  94. 94.

    Buniel MC, Geelan-Hansen K, Weber PC, Tuohy VK: Immunosuppressive therapy for autoimmune inner ear disease. Immunotherapy. 2009, 1: 425-434. 10.2217/imt.09.12.

    PubMed Central  CAS  PubMed  Google Scholar 

  95. 95.

    Baek MJ, Park HM, Johnson JM, Altuntas CZ, Jane-Wit D, Jaini R, Solares CA, Thomas DM, Ball EJ, Robertson NG, Morton CC, Hughes GB, Tuohy VK: Increased frequencies of cochlin-specific T cells in patients with autoimmune sensorineural hearing loss. J Immunol. 2006, 177: 4203-4210.

    CAS  PubMed  Google Scholar 

  96. 96.

    Bovo R, Aimoni C, Martini A: Immune-mediated inner ear disease. Acta Otolaryngol. 2006, 126: 1012-1021. 10.1080/00016480600606723.

    CAS  PubMed  Google Scholar 

  97. 97.

    Agrup C: Immune-mediated audiovestibular disorders in the paediatric population: a review. Int J Audiol. 2008, 47: 560-565. 10.1080/14992020802282268.

    PubMed  Google Scholar 

  98. 98.

    Zhou Y, Yuan J, Zhou B, Lee AJ, Lee AJ, Ghawji M, Yoo TJ: The therapeutic efficacy of human adipose tissue-derived mesenchymal stem cells on experimental autoimmune hearing loss in mice. Immunology. 2011, 133: 133-140. 10.1111/j.1365-2567.2011.03421.x.

    PubMed Central  CAS  PubMed  Google Scholar 

  99. 99.

    Muraro PA, Martin R: Immunological questions on hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transplant. 2003, 32 (Suppl 1): S41-44.

    PubMed  Google Scholar 

  100. 100.

    Vosoughi R, Freedman MS: Therapy of MS. Clin Neurol Neurosurg. 2010, 112: 365-385. 10.1016/j.clineuro.2010.03.010.

    PubMed  Google Scholar 

  101. 101.

    Constantin G, Marconi S, Rossi B, Angiari S, Calderan L, Anghileri E, Gini B, Bach SD, Martinello M, Bifari F, Galiè M, Turano E, Budui S, Sbarbati A, Krampera M, Bonetti B: Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells. 2009, 27: 2624-2635. 10.1002/stem.194.

    CAS  PubMed  Google Scholar 

  102. 102.

    Riordan NH, Ichim TE, Min WP, Wang H, Solano F, Lara F, Alfaro M, Rodriguez JP, Harman RJ, Patel AN, Murphy MP, Lee RR, Minev B: Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med. 2009, 7: 29-10.1186/1479-5876-7-29.

    PubMed Central  PubMed  Google Scholar 

  103. 103.

    Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A, Herlopian A, Baz EK, Mahfouz R, Khalil-Hamdan R, Kreidieh NM, El-Sabban M, Bazarbachi A: Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol. 2010, 227: 185-189. 10.1016/j.jneuroim.2010.07.013.

    CAS  PubMed  Google Scholar 

  104. 104.

    Ko MS, Park HG, Yun YM, Ra JC, Shin T, Lee KK: Ameliorative effects of human adipose tissue-derived mesenchymal stem cells on myelin basic protein-induced experimental autoimmune encephalomyelitis in Lewis rats. Neural Regeneration Research. 2011,

    Google Scholar 

  105. 105.

    Dalakas MC: Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010, 6: 129-137. 10.1038/nrrheum.2010.2.

    PubMed  Google Scholar 

  106. 106.

    Henes JC, Heinzelmann F, Wacker A, Seelig HP, Klein R, Bornemann A, Faul C, Kanz L, Koetter I: Antisignal recognition particle-positive polymyositis successfully treated with myeloablative autologous stem cell transplantation. Ann Rheum Dis. 2009, 68: 447-448. 10.1136/ard.2008.094755.

    CAS  PubMed  Google Scholar 

  107. 107.

    Wang D, Zhang H, Cao M, Tang Y, Liang J, Feng X, Wang H, Hua B, Liu B, Sun L: Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis. 2011, 70: 1285-1288. 10.1136/ard.2010.141804.

    PubMed  Google Scholar 

  108. 108.

    Saeki HM, Furue , Furukawa F, Hide M, Ohtsuki M, Katayama I, Sasaki R, Suto H, Takehara K: Guidelines for management of atopic dermatitis. J Dermatol. 2009, 36: 563-577. 10.1111/j.1346-8138.2009.00706.x.

    PubMed  Google Scholar 

  109. 109.

    Galli E, Cicconi R, Rossi P, Casati A, Brunetti E, Mancino G: Atopic dermatitis: molecular mechanisms, clinical aspects and new therapeutical approaches. Curr Mol Med. 2003, 3: 127-138. 10.2174/1566524033361564.

    CAS  PubMed  Google Scholar 

  110. 110.

    Ellis C, Luger T, Abeck D, Allen R, Graham-Brown RAC, De Prost Y, Eichenfield LF, Ferrandiz C, Giannetti A, Hanifin J, Koo JYM, Leung D, Lynde C, Ring J, Ruiz-Maldonado R, Saurat J-H: International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol. 2003, 148 (Suppl): 3-10. 63

    PubMed  Google Scholar 

  111. 111.

    Charman CR, Morris AD, Williams HC: Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000, 142: 931-936. 10.1046/j.1365-2133.2000.03473.x.

    CAS  PubMed  Google Scholar 

  112. 112.

    Gonzalez-Rey E, Gonzalez MA, Varela N, O'Valle F, Hernandez-Cortes P, Rico L, Büscher D, Delgado M: Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis. 2010, 69: 241-248. 10.1136/ard.2008.101881.

    CAS  PubMed  Google Scholar 

  113. 113.

    González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M: Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum. 2009, 60: 1006-1019. 10.1002/art.24405.

    PubMed  Google Scholar 

  114. 114.

    Liu Y, Mu R, Wang S, Long L, Liu X, Li R, Sun J, Guo J, Zhang X, Guo J, Yu P, Li C, Liu X, Huang Z, Wang D, Li H, Gu Z, Liu B, Li Z: Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther. 2010, 12: R210-10.1186/ar3187.

    PubMed Central  PubMed  Google Scholar 

  115. 115.

    Angelova-Fischer I, Bauer A, Hipler UC, Petrov I, Kazandjieva J, Bruckner T, Diepgen T, Tsankov N, Williams M, Fischer TW, Elsner P, Fluhr JW: The objective severity assessment of atopic dermatitis (OSAAD) score: validity, reliability and sensitivity in adult patients with atopic dermatitis. Br J Dermatol. 2005, 153: 767-773. 10.1111/j.1365-2133.2005.06697.x.

    CAS  PubMed  Google Scholar 

  116. 116.

    No authors listed: Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on atopic dermatitis. Dermatology. 1993, 186: 23-31. 10.1159/000247298.

    Google Scholar 

Download references


We thank M.S. Ko, J.H. Kang, S.J. Lee, W.J. Kim for collecting data and stimulating discussions.

Author information



Corresponding authors

Correspondence to Jeong Chan Ra or Andras Kurtz.

Additional information

Competing interest Statement

Jeong Geun Kim, Byeong Chul Kang, Yong Soon Lee, Ken Nakama, Min Piao, Betram Sohl and Andras Kurtz have no competing financial or personal interests in this work. Jeong Chan Ra, Sung Keun Kang, Il Sub Shin and Hyeong Geun Park are employees and shareholders of RNL BIO Limited, which holds patents on some of the technologies in this manuscript. San Aun Joo is employee of RNL BIO and declares no competing financial interests.

Authors' contributions

JCR: involved in the preparation and in vitro and in vivo characterization of AdMSCs and designed the protocol of stem cell treatment and managed the clinical cases along with clinicians. SAJ: designed the protocol of stem cell treatment and cared the patients. NK: cared and treated autoimmune patients. MP: cared and treated autoimmune patients. BS: cared autoimmune inner ear disease patient and evaluated the data. SKK: performed the migration and homing potential of AdMSCs and drafted and revised the manuscript. ISS: designed and performed characterization of AdMSCs including distribution, immunophenotyping and in vitro differentiation of AdMSCs. HGP: cultured AdMSCs and performed in vitro safety and stability test of AdMSCs. JGK: analyzed and evaluated the data of autoimmune inner ear disease. BKK: performed the experiments of in vivo safety of AdMSCs. YSL: designed and evaluated data of safety and distribution of AdMSCs. AK: drafted and revised the manuscript, organized and evaluated data. All authors read and approved the final manuscript

Electronic supplementary material

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Ra, J.C., Kang, S.K., Shin, I.S. et al. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med 9, 181 (2011).

Download citation


  • Autologous adipose mesenchymal stem cells
  • autoimmune diseases
  • systemic stem cell infusion